Bioventus Inc. $BVS Stock: Royce & Associates LP Decreases Holdings

Royce & Associates LP decreased its position in shares of Bioventus Inc. (NASDAQ:BVS – Free Report) by 12.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,609,160 shares of the company’s stock after selling 224,052 shares during the quarter. Royce & Associates LP owned approximately 1.91% of Bioventus worth $21,933,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its holdings in shares of Bioventus by 692.5% in the third quarter. Russell Investments Group Ltd. now owns 145,943 shares of the company’s stock valued at $1,989,000 after acquiring an additional 127,528 shares during the period. Ritholtz Wealth Management purchased a new position in shares of Bioventus during the third quarter worth approximately $320,000. Allspring Global Investments Holdings LLC grew its position in shares of Bioventus by 4.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 85,874 shares of the company’s stock worth $1,170,000 after acquiring an additional 3,367 shares during the last quarter. Covestor Ltd grew its position in shares of Bioventus by 25.6% during the third quarter. Covestor Ltd now owns 5,808 shares of the company’s stock worth $79,000 after acquiring an additional 1,182 shares during the last quarter. Finally, Signaturefd LLC increased its holdings in shares of Bioventus by 2,809.1% in the 3rd quarter. Signaturefd LLC now owns 1,920 shares of the company’s stock valued at $26,000 after acquiring an additional 1,854 shares during the period. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Wall Street Analyst Weigh In

BVS has been the subject of several research reports. Barrington Research set a $18.00 price target on shares of Bioventus in a research report on Thursday, August 6th. Canaccord Genuity Group decreased their price target on shares of Bioventus from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, November 3rd. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, August 17th. Wall Street Zen lowered shares of Bioventus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 7th. Finally, Craig Hallum restated a “buy” rating and issued a $18.00 price objective on shares of Bioventus in a research note on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $16.60.

Read Our Latest Stock Report on BVS

Bioventus Price Performance

Bioventus stock opened at $10.66 on Monday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.68 and a quick ratio of 1.16. Bioventus Inc. has a 1-year low of $6.47 and a 1-year high of $15.89. The company has a market cap of $898.21 million, a PE ratio of 13.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.66. The stock’s 50 day moving average price is $13.13 and its 200 day moving average price is $11.04.

Bioventus (NASDAQ:BVS – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.17. Bioventus had a net margin of 9.78% and a return on equity of 26.31%. The business had revenue of $142.44 million during the quarter. On average, sell-side analysts predict that Bioventus Inc. will post 0.78 EPS for the current fiscal year.

About Bioventus

(Free Report)

Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew.

Further Reading

Want to see what other hedge funds are holding BVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioventus Inc. (NASDAQ:BVS – Free Report).

Institutional Ownership by Quarter for Bioventus (NASDAQ:BVS)

Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.